InterMune Inc. dipped on news that it would stop testing the highest dose in its ongoing Phase IIb study of protease inhibitor ITMN-191 in hepatitis C virus after reports of liver toxicity in three patients, offering a minor distraction for investors awaiting FDA word on the company's new drug application for fibrosis candidate pirfenidone. (BioWorld Today) Read More
